Broadstone Net Lease stock maintains Market Outperform rating at JMP

JMP Securities and BMO Capital Markets reaffirmed their Outperform ratings on Broadstone Net Lease (BNL), driven by its expanding, high-yielding build-to-suit development program, which has reached approximately $575 million and aims for an additional $500 million this year. The company's portfolio quality has also improved significantly after exiting clinical healthcare. Despite these strengths, BNL shares trade at an approximate 2.5-turn discount to net-lease REIT peers on 2025 estimated AFFO, exceeding historical levels and highlighting potential undervaluation.

Analysis

Broadstone Net Lease (BNL) is receiving positive reinforcement from analysts at JMP Securities and BMO Capital Markets, who both maintain 'Outperform' ratings. The bullish thesis is centered on BNL's expanding build-to-suit development program, which has grown to approximately $575 million and is targeted to add another $500 million in projects this year. This strategy is viewed favorably as these development funding projects typically generate higher yields compared to traditional acquisitions. Despite this positive strategic momentum and recent earnings performance aligning with expectations, BNL's valuation presents a notable discount. The company's shares trade at approximately 11 times estimated 2025 AFFO per share, a 2.5-turn discount to the net-lease REIT peer average, which significantly exceeds the historical discount of 1.0x to 1.5x. This valuation gap exists even as the company's portfolio quality has improved following its strategic exit from clinical healthcare, an action that has enhanced cash flow quality, duration, and overall portfolio diversification.

Key Decisions for Investors

• Investors may find BNL attractive due to its significant valuation discount of 2.5 turns to its net-lease REIT peers, which is substantially wider than its historical average and may suggest potential for a valuation re-rating.
• The success of the company's high-yield build-to-suit strategy is a key catalyst; therefore, monitoring BNL's progress toward its goal of securing an additional $500 million in projects this year is crucial.
• Consider that the stock's risk profile has been actively managed through the divestment of its clinical healthcare assets, resulting in a more stable and diverse portfolio that strengthens the investment case at its current discounted valuation.